Patient advocacy foundations, with their rich knowledge of a particular disease, extensive experience funding research in their fields, and access to experts, information and patients can significantly enhance the drug discovery process.
At CTI, we provide foundations with an opportunity to leverage their resources with those of big pharma to target therapeutics in a specific disease area.
Our first foundation partnership was signed with the Alliance for Lupus Research (ALR) and announced in November 2012. CTI and its foundation partners share equal decision-making rights, including selecting projects to incorporate into CTI’s pipeline and evaluation of project progress.
CTI’s goal and that of disease foundations is the same – to provide new, targeted therapies to patients living with disease. Our hope is that by combining our resources we can speed the creation of life-saving treatments for patients who need them.